Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Operating Leases (2019 - 2025)

Historic Operating Leases for Theravance Biopharma (TBPH) over the last 7 years, with Q3 2025 value amounting to $33.7 million.

  • Theravance Biopharma's Operating Leases fell 1741.82% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.7 million, marking a year-over-year decrease of 1741.82%. This contributed to the annual value of $39.1 million for FY2024, which is 1354.67% down from last year.
  • As of Q3 2025, Theravance Biopharma's Operating Leases stood at $33.7 million, which was down 1741.82% from $35.6 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Operating Leases ranged from a high of $57.8 million in Q2 2021 and a low of $33.7 million during Q3 2025
  • In the last 5 years, Theravance Biopharma's Operating Leases had a median value of $43.8 million in 2024 and averaged $45.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first soared by 2128.24% in 2021, then plummeted by 1997.43% in 2023.
  • Over the past 5 years, Theravance Biopharma's Operating Leases (Quarter) stood at $52.7 million in 2021, then fell by 13.81% to $45.4 million in 2022, then fell by 0.38% to $45.2 million in 2023, then dropped by 13.55% to $39.1 million in 2024, then dropped by 13.88% to $33.7 million in 2025.
  • Its last three reported values are $33.7 million in Q3 2025, $35.6 million for Q2 2025, and $37.3 million during Q1 2025.